https://www.thebodypro.com/category/providing-quality-hiv-care/tag/liver

The Latest

Biden Harris

Will the Biden-Harris Administration Breathe Life Back Into Vital HIV and Hepatitis Programs?

We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.

By Terri Wilder, M.S.W.
reflect rethink revise

This Week in HIV Research: Revisiting Our Needs

Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.

By Barbara Jungwirth and Myles Helfand
BLM health care

This Week in HIV Research: The Long Road to Racial Health Justice

Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.

By Barbara Jungwirth and Myles Helfand
doctor with trans patient

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand
discover opportunities

This Week in HIV Research: The Challenges of Our Assumptions

May 28, 2020: Anal lesion recurrence among women with HIV; non-alcoholic fatty liver disease frequency in lean patients; long-term efficacy for a smoking cessation intervention; non-lymphoid cancers following lymphoid malignancy.

By Barbara Jungwirth and Myles Helfand
David Kalinoski

Creating Care Plans for People Who Use Drugs Or With Hepatitis C in the Time of Coronavirus

VOCAL-NY has kept its doors open through the COVID-19 pandemic to serve people who use drugs and may be living with hepatitis C, but how it provides services has changed.

By Terri Wilder, M.S.W.
virology

This Week in HIV Research: Is Viral Suppression an STI Prevention Tool?

March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.

By Barbara Jungwirth and Myles Helfand
Prescription medicine bottles on lipid blood test report

This Week in HIV Research: Much Ado About Lipids

Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.

By Barbara Jungwirth and Myles Helfand
Doctor is performing liver biopsy to women supporting with Ultrasound

Researchers Recommend Screening All People With HIV for Elevated Liver Function Values

Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.

By Barbara Jungwirth
Promo Image

This Week in HIV Research: Rethinking PrEP Guidelines

Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.

By Barbara Jungwirth and Myles Helfand